ArticlePharmaceutical science advances2026
Xiangsha Liujunzi Tang: A promising traditional Chinese herbal formula for healing gastric mucosal injury through pyroptosis pathway modulation.
Article in Pharmaceutical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric mucosal injury is a common gastrointestinal disorder characterized by a high recurrence rate, and current clinical treatments remain limited due to adverse reactions. Xiangsha Liujunzi Tang (XSLJZT) is a classic traditional Chinese medicine formula with well-documented gastroprotective efficacy in clinical practice; however, its underlying pharmacological mechanism, particularly its regulatory role in pyroptosis, remains poorly elucidated. In this study, bioinformatics and molecular docking were employed to identify targets and pathways associated with gastric mucosal injury. XSLJZT was manufactured and quality-controlled using the liquid chromatography-tandem mass spectrometry (LC-MS/MS). Hematoxylin-eosin (H&E) staining along with scanning electron microscopy was utilized to analyze the morphology and ultrastructure of the gastric mucosal surface. Periodic acid-Schiff (PAS) staining and ELISA were utilized to measure gastric mucosal glycoproteins and the release of pro-inflammatory and anti-inflammatory cytokines in rats with IND-induced gastric mucosal injury. Immunofluorescence was employed to detect the expression levels of GSDMD-N, p-NF-κB, p-IKKβ, NLRP3, ASC, and cleaved caspase-1 proteins to elucidate the potential molecular mechanisms underlying XSLJZT's gastroprotective effects. Bioinformatics analysis and molecular docking simulation indicated that key molecules of the NLRP3 inflammasome-mediated pyroptosis pathway are closely associated with gastric mucosal injury, and the active components of XSLJZT show potential binding interactions with these target proteins. Animal experiments demonstrated that XSLJZT significantly reduced the ulcer index and improved swelling, hemorrhage, and ulcers of the gastric mucosa. Additionally, XSLJZT administration significantly increased the levels of protective cytokines (IL-4, IL-10, and IL-12) while decreasing the levels of pro-inflammatory mediators (IL-18, IL-1β, and TNF-α). Further in vivo validation confirmed that XSLJZT markedly downregulated the protein expression of GSDMD-N, p-NF-κB, p-IKKβ, NLRP3, ASC, and cleaved caspase-1. These findings suggest that XSLJZT may exert a therapeutic effect on digestive disorders associated with gastric mucosal injury by modulating the NLRP3 inflammasome-mediated pyroptosis signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.